Critical considerations of matrix selection in LC–MS bioanalysis for toxicokinetic and pharmacokinetic assessment in drug development

References

• 1. Emmons G, Rowland M. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2(11), 1791–1796 (2010).
  CASGoogle Scholar
• 2. Rowland M, Emmons GT. Use of dried blood spots in drug development: pharmacokinetic considerations. AAPS J. 12(3), 290–293 (2010).
  Medline CASGoogle Scholar
• 3. Spruill WJ, Wade WE, Dipiro JT, Blouin RA, Pruemer JM. Lesson 2 basic pharmacokinetics. Concepts in Clinical Pharmacokinetics Lesson (6th Edition) ASHP, 21–30 (2014).
  Google Scholar
• 4. Lensmeyer GL, Wiebe DA, Carlson IH. Distribution of cyclosporin A metabolites among plasma and cells in whole blood: effect of temperature, hematocrit, and metabolite concentration. Clin. Chem. 35(1), 56–63 (1989).
  Medline CASGoogle Scholar
• 5. Gidal BE, Lensmeyer GL. Therapeutic monitoring of topiramate: evaluation of the saturable distribution between erythrocytes and plasma of whole blood using an optimized high-pressure liquid chromatography method. Ther. Drug Monit. 21(5), 567 (1999).
  Medline CASGoogle Scholar
• 6. Li W, Williams SM, Smith HT, Tse FLS. Quantitative analysis of NIM811, a cyclophilin inhibitor, in human dried blood spots using liquid chromatography–tandem mass spectrometry. J. Chromatogr. B Analyt Technol Biomed Life Sci. 879(24), 2376–2382 (2011).
  Medline CASGoogle Scholar
• 7. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24(1), 49–65 (2010).
  MedlineGoogle Scholar
• 8. Kok MGM, Fillet M. Volumetric absorptive microsampling: current advances and applications. J. Pharm. Biomed. Anal. 147, 288–296 (2018).
  Medline CASGoogle Scholar
• 9. Craig WA, Welling PG. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin. Pharmacokinet. 2(4), 252–268 (1977).
  Medline CASGoogle Scholar
• 10. Gonzalez D, Schmidt S, Derendorf H. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin. Microbiol. Rev. 26(2), 274–288 (2013).
  Medline CASGoogle Scholar
• 11. Sheu M-T, Wu C-Y, Su C-Y, Ho H-O. Determination of total and unbound docetaxel in plasma by ultrafiltration and UPLC–MS/MS: application to pharmacokinetic studies. Sci. Rep. 7(1), 14609 (2017).
  MedlineGoogle Scholar
• 12. Nation RL, Theuretzbacher U, Tsuji BT. Concentration-dependent plasma protein binding: expect the unexpected. Eur. J. Pharm. Sci. 122, 341–346 (2018).
  Medline CASGoogle Scholar
• 13. Love I, Smith GT, Hill HM. Assessment of whole blood stability and blood/plasma distribution of drugs. In: Handbook of LC–MS Bioanalysis. Li WZhang JTse FL, (Eds). John Wiley & Sons, NJ, USA, 129–138 (2013).
  Google Scholar
• 14. Fleuren HLJ, Van Rossum JM. Nonlinear relationship between plasma and red blood cell pharmacokinetics of chlorthalidone in man. J. Pharmacokinet. Biopharm. 5(4), 359–375 (1977).
  Medline CASGoogle Scholar
• 15. Li W, Zhang J, Tse FL. Strategies in quantitative LC–MS/MS analysis of unstable small molecules in biological matrices. Biomed. Chromatogr. 25(1-2), 258–277 (2011).
  MedlineGoogle Scholar
• 16. Ledvina AR, Ewles M, Pang Y, Cape S. Whole blood stability in quantitative bioanalysis. Bioanalysis 11(20), 1885–1897 (2019).
  CASGoogle Scholar
• 17. Jain DS, Subbaiah G, Sanyal M, Pande UC, Shrivastav P. Liquid chromatography–tandem mass spectrometry validated method for the estimation of indapamide in human whole blood. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 834(1-2), 149–154 (2006).
  Medline CASGoogle Scholar
• 18. Brockman AH, Hatsis P, Paton M, Wu J-T. Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood. Anal. Chem. 79(4), 1599–1603 (2007).
  Medline CASGoogle Scholar